To assess the impact of ingestion of collagen peptides on muscle connective tissue protein synthesis in vivo in humans.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
Digestie & absorptie, spier en huid
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary endpoint will be the muscle connective tissue protein synthesis
over the period before and after intake of collagen protein peptides, as
determined using stable isotope tracer methodology.
Secondary outcome
To quantify the digestion and absorption kinetics of collagen peptides and the
subsequent impact on skin connective tissue protein synthesis rates in vivo in
humans. Also, incorporation of collagen-derived amino acids in muscle &
skin tissue will be determined. Other secondary outcomes include whole-body
protein kinetics (total rate of appearance, exogenous rate of appearance,
endogenous rate of appearance, rate of disappearance), whole-body protein
metabolism (synthesis, breakdown, oxidation, net balance), overall plasma amino
acid responses, postprandial hydroxyproline concentration over time (iAUC) and
plasma insulin responses.
Background summary
Collagen protein is the central structural component of extracellular
connective tissues within skeletal muscle, bone, cartilage and skin. Dietary
collagen peptides are a promising protein source to deliver the specific amino
acid precursors required to support an increase in connective tissue protein
synthesis across several tissues (e.g. muscle, skin). However, the digestion
and absorption kinetics of collagen peptides and the subsequent impact on
muscle and skin connective tissue protein synthesis rates have not yet been
assessed in vivo in humans.
Study objective
To assess the impact of ingestion of collagen peptides on muscle connective
tissue protein synthesis in vivo in humans.
Study design
Clinical study with a single treatment pre-post design.
Intervention
All subjects will perform a single experiment where they ingest 40 g of
collagen protein peptides in 400 mL water. Before and after ingestion, blood
samples, muscle and skin biopsies will be taken at regular intervals during a
7.5 hour period.
Study burden and risks
The burden and risks with participation are small. A DEXA scan will be done to
assess body composition, where the level of radiation is very low compared to
the background radiation level in the Netherlands. Furthermore, we will ask the
participants to fill out a medical questionnaire. Insertion of the catheters
during the test day is comparable to a blood draw and could result in a small
hematoma. We will take 12 blood samples during the experimental period. The
total amount of blood we draw (120 mL) is much less than the amount of a blood
donation (500 mL) and will be completely restored in approximately 1 month.
Muscle and skin biopsies (both 3x) will be obtained under local anesthesia by
an experienced physician. The muscle biopsy may cause some minor discomfort,
which is comparable to muscle soreness or the pain one has after bumping into
the corner of a table.
Participants will come to the university two times: 1 screening (~1h) and 1
experimental day (~8h). On the experimental test day, the subjects will be
asked to remain fasted (with the exception of the experimental drinks). In
addition, subjects will be asked in the two days prior to the test days not to
perform any type of intense physical activity and to avoid consuming caffeine
and alcohol in the 12h and 24h prior to the test days, respectively.
Participants will be asked to record their nutritional intake and daily
activities in the two days prior to the experimental test days. There is no
direct benefit to the participant, only their contribution to the scientific
knowledge on digestion of collagen protein peptides and the effect on muscle
and skin connective tissue protein synthesis rates. The protein supplements are
produced according to food safety standards and are safe for human use.
Universiteitssingel 50
Maastricht 6229 ER
NL
Universiteitssingel 50
Maastricht 6229 ER
NL
Listed location countries
Age
Inclusion criteria
- Aged between 18-35 years
- Healthy, recreationally active (participating in recreational sports
activities >= 1 and <= 6 h per week, with a maximum of 2 h resistance-type
exercise)
- 18.5 <= BMI <= 30 kg/m2
- No physical limitations (i.e. able to perform all activities associated with
daily living in an independent manner).
Exclusion criteria
- Smoking
- Musculoskeletal disorders
- Metabolic disorders
- Use of any medications known to affect protein metabolism (i.e.
corticosteroids, non-steroidal anti-inflammatories, or prescribed acne
medications).
- Chronic use of gastric acid suppressing medication or anti-coagulants
- Unstable weight over the last three months
- Diagnosed GI tract disorders or diseases
- Blood donation in the past 2 months
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL81239.068.22 |
| Other | Registratie na goedkeuring METC |